Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGLV6-57 | P01721 | 1/20 | 0.40 |
| ▸ | S100B | P04271 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL150569 | 0.87 | S100B (0.50) | IGLV6-57S100BALDH1A1L3MBTL1KDM4E | |
| SCHEMBL151204 | 0.84 | APAF1 (0.37) | POLBALDH1A1KDM4EMEN1HPGD | |
| SCHEMBL972851 | 0.70 | S100B (0.47) | IGLV6-57S100BALDH1A1L3MBTL1KDM4E | |
| SCHEMBL3105610 | 0.69 | ALDH1A1 (0.35) | POLBALDH1A1KDM4EMEN1HPGD | |
| SCHEMBL150487 | 0.69 | ADRA2A (0.37) | IGLV6-57S100BADRA2AADRA2BADRA2C | |
| SCHEMBL15453003 | 0.69 | S100B (0.69) | IGLV6-57S100BADRA2AADRA2BADRA2C | |
| SCHEMBL127321 | 0.69 | ADRA2A (0.35) | IGLV6-57S100BADRA2AADRA2BADRA2C | |
| SCHEMBL31265588 | 0.69 | S100B (0.46) | IGLV6-57S100BPOLBALDH1A1L3MBTL1 | |
| SCHEMBL31265585 | 0.69 | S100B (0.46) | IGLV6-57S100BPOLBALDH1A1L3MBTL1 | |
| SCHEMBL195345 | 0.68 | MEN1 (0.45) | IGLV6-57S100BADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2430007-B1 | METHODS OF CHEMICAL SYNTHESIS OF DIAMINOPHENOTHIAZINIUM COMPOUNDS INVOLVING THE USE OF PERSULFATE OXIDANTS | WISTA LAB LTD (SG) | 2014-02-12 | — | — | EP | disclosed |
| EP-2430007-A1 | METHODS OF CHEMICAL SYNTHESIS OF DIAMINOPHENOTHIAZINIUM COMPOUNDS INVOLVING THE USE OF PERSULFATE OXIDANTS | Wista Laboratories Ltd. (SG) | 2012-03-21 | — | — | EP | disclosed |
| US-20120058995-A1 | METHODS OF CHEMICAL SYNTHESIS OF DIAMINOPHENOTHIAZINIUM COMPOUNDS INVOLVING THE USE OF PERSULFATE OXIDANTS | WISTA LABORATORIES LTD. (SG) | 2012-03-08 | — | — | US | disclosed |
| WO-2010130977-A1 | METHODS OF CHEMICAL SYNTHESIS OF DIAMINOPHENOTHIAZINIUM COMPOUNDS INVOLVING THE USE OF PERSULFATE OXIDANTS | WISTA LABORATORIES LTD. (SG) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058995-A1 | METHODS OF CHEMICAL SYNTHESIS OF DIAMINOPHENOTHIAZINIUM COMPOUNDS INVOLVING THE USE OF PERSULFATE OXIDANTS | TST, TPMT, MGMT | IGLV6-57 2306/4885S100B 962/4885ADRA2A 4308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.